Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Operating Expenses (2016 - 2025)

PAVmed has reported Operating Expenses over the past 5 years, most recently at $6.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 31.9% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $21.9 million, down 37.32%, while the annual FY2025 figure was $21.9 million, 53.93% down from the prior year.
  • Operating Expenses for Q4 2025 was $6.9 million at PAVmed, up from $4.8 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $24.7 million in Q4 2022 and troughed at $4.7 million in Q2 2025.
  • A 5-year average of $14.4 million and a median of $15.0 million in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: skyrocketed 145.44% in 2022 and later plummeted 70.19% in 2024.
  • Year by year, Operating Expenses stood at $20.0 million in 2021, then grew by 23.69% to $24.7 million in 2022, then fell by 29.46% to $17.4 million in 2023, then plummeted by 70.19% to $5.2 million in 2024, then soared by 31.9% to $6.9 million in 2025.
  • Business Quant data shows Operating Expenses for PAVM at $6.9 million in Q4 2025, $4.8 million in Q3 2025, and $4.7 million in Q2 2025.